Physician profile
Rachel Barish
NPI 1891039608
$3,744.28
in general payments reported to CMS, 2019-2025
14 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $142 · 2023: $316 · 2024: $2,854 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,320 · Food and Beverage: $1,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,320.00 |
| Food and Beverage | $1,281.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,438.44 | 2024 | Wainua |
| Abbott Laboratories | $344.95 | 2023-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Alnylam Pharmaceuticals INC. | $264.88 | 2023-2025 | Amvuttra |
| Cvrx, INC. | $169.25 | 2021-2024 | Barostim Neo System |
| Pfizer INC. | $150.37 | 2024-2025 | |
| Scpharmaceuticals INC. | $115.72 | 2025 | |
| Abbvie INC. | $98.94 | 2024 | |
| American Regent | $37.54 | 2025 | Injectafer |
| Kestra Medical Technology Services, INC. | $30.48 | 2025 | Assure Wcd |
| Novo Nordisk INC | $25.00 | 2024 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.63 | 2024 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $22.07 | 2023 | Opsumit |
| Janssen Pharmaceuticals, INC | $20.17 | 2024 | Xarelto |
| Quidel Corporation | $2.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Barish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.